Latest Caligan Partners LP Stock Portfolio
Caligan Partners LP Performance:
2025 Q4: 29.66%YTD: 136.83%2024: 25.42%
Performance for 2025 Q4 is 29.66%, and YTD is 136.83%, and 2024 is 25.42%.
About Caligan Partners LP and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Caligan Partners LP reported an equity portfolio of $1.2 Billions as of 31 Dec, 2025.
The top stock holdings of Caligan Partners LP are LQDA, , RVMD. The fund has invested 23% of it's portfolio in LIQUIDIA CORPORATION and 16.1% of portfolio in ABIVAX SA.
The fund managers got completely rid off EVOLUS INC (EOLS), MERUS N V (MRUS) and AURA BIOSCIENCES INC (AURA) stocks. Caligan Partners LP opened new stock positions in VAXCYTE INC (PCVX), TANGO THERAPEUTICS INC (TNGX) and MAZE THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to INHIBRX BIOSCIENCES INC, TYRA BIOSCIENCES INC (TYRA) and XENON PHARMACEUTICALS INC (XENE).
The top stock holdings of Caligan Partners LP are LQDA, , RVMD. The fund has invested 23% of it's portfolio in LIQUIDIA CORPORATION and 16.1% of portfolio in ABIVAX SA.
The fund managers got completely rid off EVOLUS INC (EOLS), MERUS N V (MRUS) and AURA BIOSCIENCES INC (AURA) stocks. Caligan Partners LP opened new stock positions in VAXCYTE INC (PCVX), TANGO THERAPEUTICS INC (TNGX) and MAZE THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to INHIBRX BIOSCIENCES INC, TYRA BIOSCIENCES INC (TYRA) and XENON PHARMACEUTICALS INC (XENE).
Caligan Partners LP Annual Return Estimates Vs S&P 500
Our best estimate is that Caligan Partners LP made a return of 29.66% in the last quarter. In trailing 12 months, it's portfolio return was 136.83%.
- Performance
- S&P 500
New Buys
| Ticker | $ Bought |
|---|---|
| vaxcyte inc | 78,660,200 |
| tango therapeutics inc | 33,046,900 |
| maze therapeutics inc | 22,794,400 |
| rapt therapeutics inc | 21,825,800 |
| vor biopharma inc | 9,962,970 |
| inventiva sa | 9,300,000 |
| spruce biosciences inc | 1,786,980 |
| eledon pharmaceuticals inc | 839,527 |
New stocks bought by Caligan Partners LP
Additions
| Ticker | % Inc. |
|---|---|
| inhibrx biosciences inc | 36.88 |
| tyra biosciences inc | 35.51 |
| xenon pharmaceuticals inc | 23.64 |
| revolution medicines inc | 20.64 |
| adma biologics inc | 14.26 |
| avalo therapeutics inc | 5.78 |
| exelixis inc | 1.8 |
Additions to existing portfolio by Caligan Partners LP
Reductions
Sold off
| Ticker | $ Sold |
|---|---|
| evolus inc | -25,413,100 |
| aura biosciences inc | -1,403,940 |
| merus n v | -20,426,200 |
Caligan Partners LP got rid off the above stocks
Sector Distribution
Caligan Partners LP has about 67.6% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 67.6 |
| Others | 32.4 |
Market Cap. Distribution
Caligan Partners LP has about 15.6% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- LARGE-CAP
- SMALL-CAP
- MICRO-CAP
| Category | % |
|---|---|
| MID-CAP | 40.1 |
| UNALLOCATED | 32.4 |
| LARGE-CAP | 15.6 |
| SMALL-CAP | 7.3 |
| MICRO-CAP | 4.6 |
Stocks belong to which Index?
About 57.4% of the stocks held by Caligan Partners LP either belong to S&P 500 or RUSSELL 2000 index.
- RUSSELL 2000
- Others
| Index | % |
|---|---|
| RUSSELL 2000 | 57.4 |
| Others | 42.6 |
Caligan Partners LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Caligan Partners LP
Caligan Partners LP has 20 stocks in it's portfolio. About 79.3% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. LQDA was the most profitable stock for Caligan Partners LP last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADMA | adma biologics inc | 4.52 | 3,012,510 | 54,948,100 | added | 14.26 | ||
| ANIK | anika therapeutics inc | 1.14 | 1,435,130 | 13,791,600 | unchanged | 0.00 | ||
| AURA | aura biosciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTX | avalo therapeutics inc | 1.32 | 881,533 | 16,008,600 | added | 5.78 | ||
| ELDN | eledon pharmaceuticals inc | 0.07 | 555,978 | 839,527 | new | |||
| EOLS | evolus inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| EXEL | exelixis inc | 5.60 | 1,553,260 | 68,079,500 | added | 1.8 | ||
| IVA | inventiva sa | 0.77 | 2,000,000 | 9,300,000 | new | |||
| LQDA | liquidia corporation | 23.05 | 8,118,890 | 280,021,000 | unchanged | 0.00 | ||
| MRUS | merus n v | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| PCVX | vaxcyte inc | 6.47 | 1,704,820 | 78,660,200 | new | |||
| RAPT | rapt therapeutics inc | 1.80 | 644,400 | 21,825,800 | new | |||
| RVMD | revolution medicines inc | 8.42 | 1,283,900 | 102,263,000 | added | 20.64 | ||
| SPRB | spruce biosciences inc | 0.15 | 20,514 | 1,786,980 | new | |||
| TNGX | tango therapeutics inc | 2.72 | 3,729,900 | 33,046,900 | new | |||
| TYRA | tyra biosciences inc | 2.04 | 944,257 | 24,824,500 | added | 35.51 | ||
| VOR | vor biopharma inc | 0.82 | 925,067 | 9,962,970 | new | |||
| VRCA | verrica pharmaceuticals inc | 0.63 | 923,910 | 7,677,690 | unchanged | 0.00 | ||
| XENE | xenon pharmaceuticals inc | 2.03 | 549,665 | 24,636,000 | added | 23.64 | ||
| abivax sa | 16.12 | 1,451,920 | 195,799,000 | unchanged | 0.00 | |||